First Time Loading...
A

Arecor Therapeutics PLC
LSE:AREC

Watchlist Manager
Arecor Therapeutics PLC
LSE:AREC
Watchlist
Price: 137.5 GBX Market Closed
Updated: May 6, 2024

Relative Value

The Relative Value of one AREC stock under the Base Case scenario is 736.53 GBX. Compared to the current market price of 137.5 GBX, Arecor Therapeutics PLC is Undervalued by 81%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AREC Relative Value
Base Case
736.53 GBX
Undervaluation 81%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
70
vs Industry
42
Median 3Y
20.9
Median 5Y
20.9
Industry
8.3
Forward
8.3
vs History
vs Industry
Median 3Y
-8.9
Median 5Y
-8.9
Industry
26.8
Forward
-557.2
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-8.1
Industry
23.3
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
21.4
vs History
78
vs Industry
30
Median 3Y
4.5
Median 5Y
4.5
Industry
2.6
vs History
70
vs Industry
38
Median 3Y
18.4
Median 5Y
18.4
Industry
7.5
Forward
6.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
vs Industry
1
Median 3Y
-6.6
Median 5Y
-6.6
Industry
4.5
Forward
-4.7
vs History
vs Industry
1
Median 3Y
-6.4
Median 5Y
-6.4
Industry
4.4
Forward
-4.4
vs History
vs Industry
1
Median 3Y
-6.5
Median 5Y
-6.5
Industry
5.6
vs History
vs Industry
2
Median 3Y
-6.3
Median 5Y
-6.3
Industry
3.4
vs History
70
vs Industry
38
Median 3Y
6.8
Median 5Y
6.8
Industry
5

Multiples Across Competitors

AREC Competitors Multiples
Arecor Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Arecor Therapeutics PLC
LSE:AREC
42.1m GBP 12.5 -4.5 -3.5 -3.3
US
Abbvie Inc
NYSE:ABBV
289.2B USD 5.3 60 13 19.9
US
Amgen Inc
NASDAQ:AMGN
166.7B USD 5.9 24.8 17.9 26.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD 8 26.5 17.8 19.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD 10.5 28.6 22.8 23.9
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.7 21.6 26.8
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD 2.9 166.8 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
47.8B USD 7 -10.1 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.7B USD 3.3 27.1 13.9 17.4
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6
P/E Multiple
Earnings Growth
UK
A
Arecor Therapeutics PLC
LSE:AREC
Average P/E: 55.3
Negative Multiple: -4.5
N/A
US
Abbvie Inc
NYSE:ABBV
60
405%
US
Amgen Inc
NASDAQ:AMGN
24.8
82%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.5
45%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.6
49%
AU
CSL Ltd
ASX:CSL
35.7
84%
US
Gilead Sciences Inc
NASDAQ:GILD
166.8
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -10.1 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
27.1
155%
KR
Celltrion Inc
KRX:068270
73.1
105%
EV/EBITDA Multiple
EBITDA Growth
UK
A
Arecor Therapeutics PLC
LSE:AREC
Average EV/EBITDA: 19.8
Negative Multiple: -3.5
N/A
US
Abbvie Inc
NYSE:ABBV
13
26%
US
Amgen Inc
NASDAQ:AMGN
17.9
62%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
50%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
59%
AU
CSL Ltd
ASX:CSL
21.6
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -11 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
13.9
67%
KR
Celltrion Inc
KRX:068270
44.7
109%
EV/EBIT Multiple
EBIT Growth
UK
A
Arecor Therapeutics PLC
LSE:AREC
Average EV/EBIT: 25.6
Negative Multiple: -3.3
N/A
US
Abbvie Inc
NYSE:ABBV
19.9
79%
US
Amgen Inc
NASDAQ:AMGN
26.8
98%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
50%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
61%
AU
CSL Ltd
ASX:CSL
26.8
70%
US
Gilead Sciences Inc
NASDAQ:GILD
8.8
35%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.4 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -55.8 N/A
US
Biogen Inc
NASDAQ:BIIB
17.4
75%
KR
Celltrion Inc
KRX:068270
61.6
138%

See Also

Discover More